ViaCyte is planning to file an IND and initiate clinical evaluation of the VC-01 product in patients with Type 1 diabetes around the middle of next year.
http://www.biospace.com/news_story.aspx?StoryID=317413&full=1
http://www.biospace.com/news_story.aspx?StoryID=317413&full=1
No comments:
Post a Comment